ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO1081

Mocetinostat Attenuates Renal Injury and Dysfunction via the Inhibition of HDAC in Npr1 Gene-Targeted Mutant Mouse Models

Session Information

Category: Hypertension

  • 1102 Hypertension: Basic and Experimental - Renal Causes and Consequences

Authors

  • Kumar, Prerna, Tulane University Health Sciences Center and School of Medicine, New Orleans, Louisiana, United States
  • Nguyen, Christian, Tulane University Health Sciences Center and School of Medicine, New Orleans, Louisiana, United States
  • Gogulamudi, Venkateswara R, Tulane University Health Sciences Center and School of Medicine, New Orleans, Louisiana, United States
  • Samivel, Ramachandran, Tulane University Health Sciences Center and School of Medicine, New Orleans, Louisiana, United States
  • Pandey, Kailash Nath, Tulane University Health Sciences Center and School of Medicine, New Orleans, Louisiana, United States
Background

Mice lacking functional guanylyl cyclase/natriuretic peptide receptor-A (GC-A/NPRA) gene (Npr1) exhibit hypertension and heart failure. The objective of the present study was to elucidate the effect of class I histone deacetylase (HDAC) inhibitor, mocetinostat (MGCD) on the regulation of Npr1 expression and repair of renal injury and dysfunction in Npr1 heterozygous mutant mice.

Methods

Male Npr1 gene-disrupted heterozygous (1-copy; Npr1+/-), wild-type (2-copy; Npr1+/+) and gene-duplicated (3-copy; Npr1++/+) mice were injected intraperitonealy with MGCD (2 mg/kg) at alternate days for 2-weeks.

Results

The treatment with MGCD significantly increased renal NPRA protein and cGMP levels in all three mice genotypes (Npr1+/-, Npr1+/+, and Npr1++/+) compared with vehicle-treated controls. The Npr1+/- mice exhibited significantly increased renal HDAC activity and HDAC1/2 protein levels compared with Npr1+/+ and Npr1++/+ mice. MGCD treatment attenuated HDAC activity by 48% and HDAC1/2 protein levels by 42% in Npr1+/- mice compared with wild-type mice. Heterozygous Npr1+/- mice exhibited higher systolic blood pressure (SBP, mm Hg) (130 ± 6 vs. Npr1+/+, 102 ± 3 and Npr1++/+ mice, 93 ± 3) and lower creatinine clearance (µl/min) (51 ± 10 vs. Npr1+/+ mice, 130 ± 14; p < 0.05). MGCD-treated Npr1+/- mice showed significantly reduced SBP (106 ± 3; p < 0.001) and increased creatinine clearance (105 ± 13; p < 0.05) compared with vehicle-treated Npr1+/- mice. Higher urinary total protein and albumin to creatinine ratios were also detected in Npr1+/- mutant mice compared with Npr1+/+; however, both of these parameters were dramatically reversed after MGCD treatment.

Conclusion

The present results demonstrate that HDAC inhibitor, MGCD upregulates Npr1 expression in vivo and repairs renal injury in Npr1+/- mice. These findings will have important implications in the treatment and prevention of hypertension and renal injury and dysfunction in humans.

Funding

  • Other NIH Support